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588I n females, ovarian granulosa cellantim€ullerian hormone (AMH)expression can be detected from
the second trimester onward until late
fertile age (1, 2). Antim€ullerian hormone
is a transforming growth factor-b
family protein that is mainly secreted
from developing follicles of 5–8 mm,
and secretion extends up to small
antral stage (3, 4). Previous studies
have demonstrated a role for AMHVOL. 111 NO. 3 / MARCH 2019
Fertility and Sterility®in sustaining the ovarian follicle pool by restricting early
recruitment of primordial follicles and FSH-dependent
preantral follicle growth (4–6). Given that in clinical settings
AMH correlates well with the ovarian antral follicle count, it
has been used as a marker of ovarian follicle reserve and to
guide clinical practice, especially in the IVF setting (2, 7, 8).
During pregnancy, levels of circulating AMH decline as a
result of ovarian down-regulation and cessation of
folliculogenesis brought about by placental steroids, but a
rapid postpartum increase can be detected (9). Until recently
AMHwas considered to be simply amarker of ovarian reserve;
however, AMH receptor 2 (AMHR2) expression has been
detected in human endometrium and placenta and recently
also in GnRH neurons (10–12).
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder of fertile-aged women, affecting approxi-
mately 10%–18% of the population when Rotterdam criteria
are applied (13, 14). According to the consensus, PCOS can
be diagnosed if at least two of the following criteria are
fulfilled: oligo- or anovulation, clinical and/or biochemical
hyperandrogenism, and polycystic ovaries (PCOs) (15).
Given that women with PCOS have higher AMH levels until
their late reproductive years compared with women without
PCOS, it has been suggested that high AMH levels could
be used as a surrogate for PCOs detected in ultrasonography
(2, 16–18). As for phenotypic alterations, levels of AMH
are highest in women with PCOS fulfilling all three
diagnostic criteria (19, 20). Moreover, in vitro granulosa
cells from anovulatory polycystic ovaries show higher AMH
expression than granulosa cells from ovulatory polycystic
ovaries (21). In addition, obesity seems to reduce AMH
levels, and in clinical practice high AMH levels are
particularly detected in lean women with PCOS showing
high LH levels (19). Indeed, a recent study revealed AMHR2
expression in hypothalamic GnRH neurons both in
mice and in humans, and AMH was able to modify
GnRH-a-neuron pulse frequency and cause alterations in
LH pulsatility, leading to a PCOS-like phenotype in mice
and raising the question of whether AMH could be involved
in the early development of PCOS in humans as well (11).
Even though PCOS is strongly hereditary, known genetic
factors explain only a small fraction of the cases (22). Genetic
studies specifically focused on AMH or AMHR2 have also
failed to unravel the origins of PCOS (23, 24), There is,
however, evidence from animal models that gestational
hyperandrogenism is able to induce a PCOS-like phenotype in
female offspring, although themechanism behind hyperandro-
genism arising during pregnancy remains unsolved (25–27).
Interestingly, a recent study in mice showed that high
gestational AMH exposure at late pregnancy resulted in a
PCOS-like phenotype in female offspring, suggesting a possible
role for AMH in the transgenerational pathogenesis of PCOS
(28). Antim€ullerian hormone was able to reduce placental aro-
matase activity, thus resulting in high androgen levels in the
dams as well as in the offspring later in life. The investigators
also reported high AMH levels in second-trimester serum sam-
ples from women with PCOS compared with controls without
PCOS (28). The aim of the present study was to assess serum
AMH and steroid hormone levels in pregnant women withVOL. 111 NO. 3 / MARCH 2019PCOS in term pregnancies. We also planned on investigating
differences in these hormonal parameters according to sex of
the offspring, because it has been shown that daughters of
women with PCOS have elevated levels of AMH (29, 30).
MATERIALS AND METHODS
Study Population
The study population consisted of 74 pregnant women: 25
women with PCOS and 49 healthy controls. The samples
were derived from the ‘‘biology, affect, stress, imaging and
cognition in pregnancy and puerperium’’ cohort (BASIC),
concerning biological correlates of mood and anxiety disor-
ders during pregnancy and the postpartum period (31). All
pregnant women in Uppsala County, Sweden, are invited to
participate in the study at their routine ultrasound screening
at gestational week 16–18. Eligible women are older than
18 years, speak Swedish, and have no blood-borne diseases.
The ultrasonographic examinations were carried out at
Uppsala University Hospital. Placental tissues were collected
between April 2012 and September 2013, and in all, 957
placental samples have been collected. Among these, women
with PCOS were identified in the hospital patient register by
International Classification of Diseases, 10th Revision diag-
nosis of polycystic ovary syndrome (E282). Altogether 25
women with a confirmed PCOS diagnosis and uncomplicated
term pregnancies were identified. Six of the women had poly-
cystic ovaries, hyperandrogenism, and oligoamenorrhea,
whereas 19 had polycystic ovaries and oligoamenorrhea.
Two healthy controls with no record of PCOS or anovulatory
infertility were chosen for each woman with PCOS and
matched for age, body mass index (BMI), and gestational
length. Detailed characteristics of the study populations are
shown in Supplemental Table 1 (available online). All women
were Caucasian except for one control subject, whowas South
American. Because the subject with the South American
background did not present as an outlier in any of the ana-
lyses, she was included in the final analyses. The study and
sample collection were approved by the research ethics com-
mittees of the University of Uppsala, Sweden and Oulu Uni-
versity Hospital, Finland.Blood Samples
In all women, a venous blood sample was drawn upon admis-
sion to the delivery ward. Serum, ethylenediaminetetraacetic
acid plasma, or lithium-heparin plasma samples were stored
at 70C.Laboratory Methods for AMH, Steroid Hormone,
and LH Analysis
Antim€ullerian hormone concentrations were assayed in
lithium-heparin plasma, ethylenediaminetetraacetic acid
plasma, or serum samples, according to sample availability,
at HUSLAB (Helsinki, Finland) using the Elecsys AMH Plus
method (Roche Diagnostics). The availability for the sample
type was similar between the study groups, and further anal-
ysis showed similar median AMH values between different
sample types, and in nonparametric Kruskal-Wallis test no589
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tween the sample types in either of the groups (data not
shown).
Concentrations of P 17-hydroxoprogesterone (17OHP),
androstenedione (A), DHEAS, T, E2, estrone (E1), and E1-3-
sulfate were measured in lithium-heparin plasma at the
Core Facility for Metabolomics, University of Bergen, by
using liquid chromatography–tandem mass spectrometry.
Serum LH was measured by immunoassay (LH ELISA;
Demeditec Diagnostics).PC
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(A) Levels of AMH were significantly higher in women with PCOS
(n ¼ 25) than in control women (n ¼ 49) at term. (B) AMH levels of
women carrying a female fetus (n ¼ 34) were higher than those of
women carrying a male fetus (n ¼ 41). The horizontal line in each
plot corresponds to the median value. The vertical line represents
the 25th–75th percentile range. Comparisons between groups
were performed using unpaired nonparametric two-tailed Mann–
Whitney U tests. *P<.05; ***P<.001.
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Differences in variables in the two study groups were analyzed
by using the independent-samples t test of theMann–Whitney
U test. For correlation and linear regression analysis, nonnor-
mally distributed parameters were square root transformed.
Correlations between steroid hormones and AMH levels were
assessed by using Pearson's correlation. The impact of BMI,
age, and gestational length was standardized by multiple
linear regression analysis. Differences between slopes were as-
sessed by ANCOVA. Risk ratios were estimated for the highest
AMH quartile (cutoff value of >1.84 ng/mL, based on the
highest quartile in the whole data set). The limit of statistical
significance was set to P%.05. Statistical analyses were per-
formed using IBM-SPSS Statistics (version 24.0.0.1) and
GraphPad Prism (version 7.03) software. Because patient
data were missing in some cases and different analyses
required different blood sample types, the number of subjects
varied between analyses.
RESULTS
Women with PCOS Have Higher Circulating AMH
and Steroid Hormone Levels at Term
Circulating AMH levels in women with PCOS at term were
twofold higher than the levels in control women (median
levels 1.61 vs. 0.71 ng/mL, P< .001; Fig. 1A). In the present
dataset, 16 of 25 women with PCOS (64%) had AMH values
higher than the interquartile range for the controls
(Fig. 1A). In addition, 14% of controls had AMH values in
the highest quartile of the whole dataset, compared with
40% in the PCOS group. Similarly to AMH, plasma A and T
levels were higher in women with PCOS than in controls
(P< .05; Supplemental Fig. 1C, D). Levels of P, 17OHP,
DHEAS, E2, E1, and E1-3-sulfate levels were comparable in
the PCOS and control groups, whereas LH levels were unde-
tectable at term (Table 1).Correlation of AMH with Steroid Levels and with
Maternal Age and Gestational Length
When analyzing the whole study population, AMH levels had
positive correlations with those of T (r ¼ 0.452, P< .001) and
A (r ¼ 0.524, P< .001), and adjustment for age and BMI had
no effect on the coefficients (data not shown). After sepa-
rating the data into cases and controls, the correlation be-
tween AMH and T was moderate but statistically significant
in control women (r ¼ 0.378, P¼ .012) and nearly significant
in women with PCOS (r ¼ 0.403, P¼ .051). After adjustment590for age, BMI, and gestational length, moderately significant
correlations were observed in both groups, without any statis-
tically significant difference between them (Table 2). For A,
the unadjusted correlation was significant only in the control
group (r ¼ 0.501, P¼ .001), whereas in women with PCOS the
correlation was weaker and did not reach statistical signifi-
cance (r ¼ 0.361, P¼ .083). However, after adjusting for
age, BMI, and gestational length, A levels correlated with
those of AMH in both groups, with no significant difference
between them. Before adjustment, E2 levels did not correlate
with those of AMH in either group, although a positive trend
was observed in the PCOS group (r ¼ 0.378, P¼ .068). After
adjusting for BMI and age, E2 levels correlated moderately
with those of AMH in women with PCOS (r ¼ 0.445,
P¼ .048), and after additional adjustment for gestational
length the trend remained (r ¼ 0.412, P¼ .069). There was
no correlation between AMH and E2 levels in the control
group before or after adjustments. A difference in slopes
was detected between the groups as regards E2 and E1
(Table 2). When correlations were studied only within the
highest AMH quartile in the data set (>1.84 ng/mL), E2 corre-
lated strongly with AMH in the PCOS group (r ¼ 0.752,
P¼ .012), but no correlations could be detected in controls
(r ¼ 0.371, P¼ .412) (data not shown). In the PCOS groupVOL. 111 NO. 3 / MARCH 2019
TABLE 1
Hormonal parameters in the study groups.
Parameter n Mean/median SD/IQR P value
AMH (ng/mL) < .001*
PCOS 25 1.61 1.04–2.45 .080
Control 49 0.71 0.46–1.26
P (nmol/L)
PCOS 24 465 134
Control 43 402 147
17OHP (nmol/L) .234
PCOS 24 21.3 8.04
Control 43 19.2 8.60
A (nmol/L) .019**
PCOS 24 8.77 5.82–11.29
Control 43 6.25 3.84–8.98
T (nmol/L) .027**
PCOS 24 3.64 2.47–4.55
Control 43 2.57 1.69–3.82
DHEAS (mmol/L) .844
PCOS 24 1.30 0.84–1.97
Control 43 1.22 0.87–2.05
E2 (nmol/L) .101
PCOS 24 82.1 31.5
Control 43 70.7 33.8
E1 (nmol/L) .073
PCOS 24 38.9 21.3–56.0
Control 43 27.4 15.9–36.1
Estriol (nmol/L) .266
PCOS 24 39.8 24.6–67.2
Control 43 33.9 22.1–48.9
ES (nmol/L) .756
PCOS 24 461 300–790
Control 43 437 225–910
LH (mIU/mL) ND
PCOS 6 <1.27 ND
Control 24 <1.27 ND
Note: Normally distributed data are presented as mean and standard deviation (SD) and
skewed data as median and interquartile range (IQR). Differences between groups were
determined by using independent-samples t-test or the nonparametric Mann–Whitney U
test. ES ¼ E1-3-sulphate; ND ¼ not detectable.
* P< .001.
** P< .05.
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TABLE 2
Correlation of AMH and steroid hormones in the study populations.
Parameter Pearson coefficient P value Standardized coe
A
PCOS 0.361 .083 0.370
Control 0.501 .001*** 0.398
T
PCOS 0.403 .051 0.447
Control 0.378 .012* 0.361
E2
PCOS 0.378 .068 0.445c
Control 0.123 .430 0.028c
E1
PCOS 0.351 .093 0.351c
Control 0.052 .739 0.019c
Note: Pearson's correlation was run to assess the relationship between AMH concentration and stud
sion analysis.
a Standardized by age and BMI at the start of pregnancy.
b Standardized by age, BMI at the start of pregnancy, and gestational length.
c Significant difference between slopes.
* P< .05.
** P< .01.
*** P< .001.
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Fertility and Sterility®AMH levels did not correlate with maternal age or gestational
length, whereas in controls AMH levels correlated negatively
with maternal age (r ¼ 0.427, P¼ .004) but not with gesta-
tional length (Supplemental Fig. 1). The coefficients for AMH
vs. age were significantly different between groups (P¼ .013).Risk Factors for High AMH Levels in Term
Pregnancy
The cutoff value for high AMH levels was set on the basis of
the highest quartile in the data set (>1.84 ng/mL). Seventeen
women (23%) had AMH values higher than the cutoff value:
10 women with PCOS (40%) and 7 controls (14%). Women
with PCOS had a 3.67-fold greater risk of being in the highest
AMH quartile compared with controls, and the risk was only
slightly reduced after adjusting for BMI and age (odds ratio
3.35; 95% confidence interval 1.04–10.82). Elevated T and
A levels increased the likelihood of being in the highest
AMH quartile. Adjustment for BMI and age did not affect
the risk (Supplemental Table 2). Steroid hormones other
than T or A did not show risk association with high AMH
levels (Supplemental Table 2).Differences in the Levels of AMH, A, T, and E2 can
only be Detected in Women with a Female Fetus
When all women with female fetuses were compared with all
women carrying a male fetus, the levels of AMH, A, and T
were significantly lower in women with female fetuses
(Fig. 1B). In the sample set we had 8 pregnancies with female
fetus in women with PCOS and 24 pregnancies in controls.
After analyzing AMH and steroid levels according to fetal
gender in the different study groups, we observed that in
women with a female fetus, the levels of AMH, A, T, and E2
were significantly higher in women with PCOS compared
with controls (Fig. 2). When comparing women with PCOS
and controls carrying a male fetus, the hormones levels did
not differ between the groups.fficienta P valuea Standardized coefficientb P valueb
.088 0.464 .035*
.009** 0.386 .009**
.040* 0.663 .003*
.047* 0.342 .027*
.048* 0.412c .069
.868 0.034c .829
.113 0.377c .088
.898 0.026c .857
y parameters. Adjustment for age, BMI, and gestational length was carried out by linear regres-
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Differences in levels of AMH, A, T, and E2 between women with PCOS and controls, according to gender of the offspring. The data showed
significant differences in AMH and steroid hormone levels, especially in pregnancies with a female fetus. Numbers of subjects in groups for
AMH analysis (A): all (PCOS ¼ 25, control ¼ 49), women with a female fetus (PCOS ¼ 8, control ¼ 25), women with a male fetus (PCOS ¼ 17,
control ¼ 24). Numbers of subjects in groups for steroid analysis (B–D): all (PCOS ¼ 23, control ¼ 45), women with a female fetus (PCOS ¼ 8,
control ¼ 24), women with a male fetus (PCOS ¼ 16, control ¼ 19). The box represents the 25th–75th percentile range and the horizontal line
the median. The whiskers represent minimum and maximum values. Differences between groups were determined by using nonparametric
Mann–Whitney U tests. *P<.05; **P<.01.
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Recently AMH has been shown to have extragonadal func-
tions: AMHR2 was shown to regulate GnRH neuron activity
and LH pulsatility, contributing to high LH levels, ovarian
cysts, and high androgen levels in mice (11). Moreover, new
data also suggest a possible role for AMH in transgenerational
PCOS pathogenesis because high gestational AMH levels in
mice resulted in a hyperandrogenic PCOS-like phenotype in
adult female offspring (28). The present study shows for the
first time that elevated AMH and androgen levels can be de-
tected at term pregnancies in women with PCOS. We also
report novel data on the correlation between gestational
AMH and androgen levels in humans in late pregnancy in a
time window sensitive to trigger PCOS-like phenotype in
offspring in animal models (25, 28).
High AMH levels have been reported in nonpregnant
women with PCOS in several previous studies (2, 19, 32).
This also applies to PCOS pregnancies during the second
trimester (28) and here at late third trimester, because the
women at term presented with two-fold greater AMH levels
compared with controls, although the levels were signifi-
cantly lower than reported in nonpregnant women with
PCOS. Indeed, AMH levels have been shown to decrease as
gestation advances, and this has been postulated to be a result
of suppressed gonadotropin release (33) and inhibition of
follicular recruitment due to placental estrogen and P secre-
tion (34), although some follicular recruitment seems to occur
even during pregnancy (9). There was overlap in AMH levels
between the PCOS and control groups. Whether high AMH
levels are more detrimental in PCOS pregnancies cannot be
concluded from these data.
This study reveals for the first time that at term, circu-
lating AMH levels correlate with those of T and A both in
women with PCOS and in controls when adjusted for age,
BMI, and gestational length. A recent study by Tata et al.
(28) showed decreased placental aromatase activity in mice
exposed to high AMH levels during late pregnancy, resulting
in high androgen levels in the dams and in female offspring in
adulthood. In humans, AMH has been shown to modify the
enzymatic activity of steroid hormone synthesis (35), and
women with PCOS have been reported to have reduced
placental aromatase activity and increased steroidogenic ac-
tivity (36), giving support to the findings of Tata et al. also in
humans. Because gestational AMH levels correlated with
those of androgens in the controls as well, it would be of in-
terest to investigate whether women with PCOS are especially
sensitive to AMH-related androgen modulation in the
placenta during pregnancy, resulting in high androgen expo-
sure in the fetus.
Besides androgens, we also detected a positive correlation
between AMH and E2 levels in pregnant women with PCOS
that was not observed in the control group. We also noticed
that in the highest AMH quartile, E2 levels correlated with
AMH only in the PCOS group. In nonpregnant women with
PCOS, E2 has been reported to correlate with AMH both nega-
tively (37) and positively (38), but in most studies no correla-
tion has been detected (24, 32, 39). Previously an in vitro
study demonstrated a lack of E2-mediated AMH down-VOL. 111 NO. 3 / MARCH 2019regulation in granulosa cells from women with PCOS (40).
Thus, it is plausible that high E2 levels would not inhibit
AMH production in the ovaries of women with PCOS, as
they would do in controls, and this could also be the case dur-
ing pregnancy, again supporting the idea of an existing
ovarian activity during pregnancy. On the other hand, periph-
eral conversion of androgens to estrogens in fat tissue might
be more pronounced in women with PCOS also presenting
with high AMH levels, and this might explain the correlation
(9). In the present study AMH levels correlated negatively
with maternal age only in the control group, but not in
PCOS, in line with previous data (41). Even though AMH
levels also decrease during aging in women with PCOS,
they remain high until late reproductive years, and the corre-
lationsmay not be as obvious as in controls during these years
(2, 42). The nonexisting correlation between AMH levels and
gestational length in the two groups most likely results from
the fact that the samples were all from term pregnancies, with
a maximum difference in length of 6 weeks.
Interestingly, when the whole study population was
analyzed, AMH levels were lower in pregnancies with a fe-
male fetus, in line with a previous report (43), although con-
tradictory data also exist (33, 41). Moreover, the levels of
AMH, T, A, and E2 were significantly higher in women with
PCOS carrying a female fetus when compared with controls
with a female fetus, and no differences were found between
groups in pregnancies with male fetuses. In line with this,
Caanen et al. (44) have also detected higher T and A
concentrations in maternal circulation throughout the
pregnancies of women with PCOS who are carrying a
female fetus, but no fetal gender-specific differences in
maternal serum androgen concentrations in women with
PCOS were detected in a third study (36). Additional studies
that support the idea of fetal gender influencing maternal ste-
roid levels also exist: Maliqueo et al. (45) reported fetal
gender-specific differences in placental aromatase expres-
sion, and Kallak et al. (27) detected a maternal AMH genotype
correlating with maternal T levels in pregnancies with a male
fetus. In any case, it is worth noting that the existing studies,
including ours, have concerned limited populations, and
larger studies are warranted in the future to address these
questions.
Our study has some limitations, and some matters remain
unsolved. Even though women with PCOS were more than
three times more likely to have AMH values in the highest
quartile, some of the values overlapped with those of control
women. The range of AMH values was broader in controls,
even though the median AMH value was lower. Thus, simi-
larly to comparison in AMH levels between nonpregnant
women with PCOS and controls, there are pregnant women
without PCOS who have relatively high circulating AMH con-
centrations but who have no current reproductive dysfunc-
tion or PCOS symptoms. It is possible that tissue-specific
AMH responses are altered in women with PCOS compared
with counterparts without PCOS. Indeed, it has been shown
that granulosa cells of oligoanovulatory women with PCOS
display altered AMH and AMHR2 expression after steroid or
LH exposure compared with normo-ovulatory women,593
ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYsupporting this theory (21, 40). Whether this applies also to
placental tissue remains to be investigated in future studies.
Owing to the limited number of participants with avail-
able samples and clinical data, we were not able to analyze
the material according to specific PCOS phenotypes or mea-
sure sex hormone–binding globulin or FSH levels. The limited
number of samples applies especially on the analysis related
to offspring gender-specific differences between the study
groups, warranting confirmation by larger studies. Moreover,
because obesity has been associated with lower AMH levels
(19) and higher gestational T levels (45), and because only a
few of the participants in the present study were obese, further
studies are needed to investigate whether AMH correlates
with androgen levels in obese pregnant women with PCOS.
In addition, all the samples were from uncomplicated term
pregnancies, thus the association of AMH with pregnancy
complications remains to be analyzed in other studies.
Furthermore, it would be of interest to study AMH and
androgen levels throughout PCOS pregnancy and determine
whether AMH and androgen levels correlate with the levels
in the offspring after birth.
To conclude, the present study shows for the first time that
pregnant women with PCOS have higher AMH and androgen
levels at term compared with controls without PCOS, and the
levels of AMH correlate with those of A and T. The differences
between the study groups were observed especially in pregnan-
cies carrying female offspring, possibly implying that that
these pregnancies are more susceptible to steroid hormone–
related changes. In light of these findings, it is possible that a
link between high AMH levels and gestational hyperandrogen-
ism exists in some women. Future studies are warranted to
investigate the role of AMH in placental function and transge-
nerational pathogenesis of PCOS in humans.
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ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYLos niveles de hormona antim€ulleriana y esteroidea circulantes se mantienen altos en mujeres embarazadas a termino con síndrome de
ovario poliquístico
Objetivo: Investigar la concentracion plasmatica de hormona antimulleriana (AMH) y su relacion con los niveles de hormonas ester-
oides en mujeres embarazadas a termino con síndrome de ovario poliquístico (PCOS) y controles.
Dise~no: Estudio de casos y controles.
Entorno: Hospital afiliado a la universidad.
Paciente(s): Un total de 74 mujeres embarazadas a termino: 25 mujeres con PCOS (edad 31,6  3,9 a~nos [media  desviacion estan-
dar], índice de masa corporal 24,0 3,9 kg/m2, duracionmedia de la gestacion 279 9 días) y 49 controles (edad 31,7 3,3 a~nos, índice
de masa corporal 24,0  3,3 kg/m2, duracion media de la gestacion 281  9 días).
Intervencion(es): Ninguna.
Principales variables: Niveles plasmaticos de AMH y de hormonas esteroides.
Resultado(s): Los niveles de hormona antim€ulleriana, T, y androstenediona fueronmayores enmujeres con SOP a termino comparados
con los controles, mientras que los niveles de estrogeno y P fueron similares. Las diferencias fueron pronunciadas en mujeres portadoras
de un feto femenino. Los niveles de testosterona y AMH se correlacionaron positivamente en ambos grupos, pero los niveles de E2 solo
en mujeres con PCOS.
Conclusion(es): Las mujeres embarazadas con PCOS presentan niveles elevados de AMH y androgenos incluso a termino, sugiriendo
un desequilibrio hormonal durante el embarazo con PCOS. Las diferencias fueron detectadas especialmente en los embarazos con un
feto femenino, lo que plantea la cuestion de si los embarazos femeninos son mas susceptibles a los efectos de la AMH y de las hormonas
esteroides.596 VOL. 111 NO. 3 / MARCH 2019
SUPPLEMENTAL FIGURE 1
r (PCOS): 0.101, p = 0.613
r (control): -0.427, p = 0.004
p (difference) = 0.028
r (PCOS): -0.244, p = 0.251
r (control): -0.277, p = 0.72
p (difference) = 0.904
Maternal age correlated with square-root-transformed AMH levels only in the control group and not in women with PCOS. There was a significant
difference between the slopes (studied by analysis of covariance). The correlations between AMH and gestational length were nonsignificant and
equal in both groups. PCOS, black circles (C), continuous line; controls, white circles (B), dotted line.
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